Section Review—Central & Peripheral Nervous Systems: Tachykinin Antagonists in Development

References

• SNIDER RM, CONSTANTINE J\XT, LOWE III JA, LONGO KP,LEBEL WS, WOODY HA, DROZDA SE, DESAI MC, VINICK FJ, SPENCER RW, HESS HJ: A potent nonpeptide antago-nist of the substance P (NK-1) receptor. Science (1991) 251:435–437.
   PubMed Web of Science ®Google Scholar
• REGOLI D, NGUYEN QT, JUK1C D: Neurokinin receptorsubtypes characterized by biological assays. Life Sci. (1994) 54(26):2035–2047.
   PubMed Web of Science ®Google Scholar
• SODEN P, WOODRUFF GN; Presence of NK3-sensitiveneurones in different proportions in the medial ha-benula of guinea-pig, rat and gerbil. Br. J. Pharmacol. (1994) 112(3):717–719.
   PubMed Web of Science ®Google Scholar
• NGUYEN OT, JUKIC D, CHRETIEN L, GOBEIL F, BOUSSOU-GOU M, REGOLI D: Two NK3 receptor subtypes. Demon-stration by biological and binding assays. Neuropeptides (1994) 27 (3): 157–161.
   Google Scholar
• MAGGI AC, PATACCHINI R, ROVERO P., GIACHE111 A: Tachykinin receptors and tachykinin receptor antago-nists. J. Auton. Pharmacol. (1993) 13:23–93.
   Google Scholar
• REGOLI D, BOUDON A, FAUCHERE JL: Receptors and • antagonists for substance P and related peptides. Phar-macol. Rev. (1994) 46(4):551–599. A recent and extensive review on neurokinin pharmacology.
   Google Scholar
• COGE F, REGOLI D: NK1 and NK2 receptors are similar In man and rabbit. Neuropeptides (1994) 26(6):385–390.
   PubMed Web of Science ®Google Scholar
• BONNER Molecular structure of receptors: 6-protein-coupled receptors. Can. J. Physiol. Pharmacol. (1994) 72\(Suppl. 1):68.
   Google Scholar
• ZENG XP, BURGHER E: Use of selective antagonists for further characterization of tachykinin NK2, NKi and possible peptide-selective receptors in guinea pig bron-chus. J. Pharmacol. Exp. Ther. (1994) 270(3):1295–1300.
   PubMed Web of Science ®Google Scholar
• LA'VIELLE S, BRUNISSEN A, CARRUE I IE A, GARRET C,CHASSAING G: Highly potent substance P antagonists substituted with beta-phenyl- or beta-benzyl-proline at position 10. Eur. J. Pharmacol. (1994) 258(3):273–276.
   Google Scholar
• HALL JM, MITCHELL D, MORTON IKM: Typical and atypical NK 1 tachykinin receptor characteristics in the rab-bit isolated iris sphincter. Br. J. Pharmacol. (1994) 112(3):985–991. One example of the pharmacological detection of two different NKi receptors subtypes within a single tissue.
   Google Scholar
• GARCIA M, SAKAMOTO K, SHIGEKAWA M, NAKANISHI S,ITO S: Multiple mechanisms of arachidonic acid release in chinese hamster ovary cells transfected with cDNA of substance P receptor. Biochem. Pharmacol. (1994) 48(9):1735–1741.
   PubMed Web of Science ®Google Scholar
• CANNING BJ, UNDEM IV: Evidence that antidromicallystimulated vagal afferents activate inhibitory neurones innervating guinea-pig trachealis. J. Physiol. Lond. (1994) 480:613–625.
   Google Scholar
• DELAUNOIS A, GUSTIN P, ANSAY M: Modulation of theacetykholine- and substance P-induced pulmonary edema by calcitonin gene-related peptide in the rabbit. J. Pharmacol, Exp. Then (1994) 270(1):30–36.
   PubMed Web of Science ®Google Scholar
• SAKAMOTO T, TSUKAGOSHI H, BARNES PJ, CHUNG KF: Involvement of tachykinin receptors (NIQ and NK2) in sodium metabisulfite-induced airway effects. Amer. J. Respir. Crit. Care Med. (1994) 149(2):387–391.
   PubMed Web of Science ®Google Scholar
• JOOS GF, KIPS JC, PAUWELS RA: In vivo characterization of the tachykinin receptors involved in the direct and indirect bronchoconstrictor effect of tachykinins in two inbred rat strains. Amer. J. Respir. Crit. Care Med. (1994) 149(5):1160–1166.
   PubMed Web of Science ®Google Scholar
• LILLY CM, BESSON G, ISRAEL E, RODGER IW, DRAZEN JM:Capsaicin-induced airway obstruction in tracheally perfused guinea pig lungs. Amer. J. Respir. Crit. Care Med. (1994) 149(5):1175–1179.
   PubMed Web of Science ®Google Scholar
• RAMNARINE SI, HIRAYAMA Y, BARNES PJ, ROGERS DF: Sensory-efferent neural control of mucus secretion. Characterization using tachykinin receptor antagonists In ferret trachea in vitro. Br. J. Pharmacol. (1994) 113(4):1183–1190. Interesting conclusion concerning the therapeutic potential of dual NKi/NK2 antagonists in asthma.
   Google Scholar
• BROKAW JJ, WHITE GW: Differential effects of phos-phoramidon and captopril on NI(.1 receptor-mediated plasma extravasation in the rat trachea. Agent Action (1994) 42(1–2):34–39.
   Google Scholar
• NAKAJIMA N, ICHINOSE M, TAKAHASHI T, YAMAUCHI H,IGARASHI A, MIIJRA M, INOUE H, TAKISHIMA T, SHIRATO K: Bradykinin-induced airway inflammation. Contribu-tion of sensory neuropeptides differs according to airway site. Amer.J. Respir. Crit. Care Med. (1994) 49(3):694–698.
   Google Scholar
• BUCKLEY TL, NIJKAMP FP: Mucosal exudation associatedwith a pulmonary delayed-type hypersensitivity reac-tion in the mouse. Role for the tachykinins. J. Immunol. (1994) 153(9):4169–4178.
   PubMed Web of Science ®Google Scholar
• MOLIMARD M, MARTIN CAE, NALINE E, HIRSCH A, AD-VENTER C: Contractile effects of bradykinin on the Isolated human small bronchus. Amer.J.Respir. Crit. Care Med. (1994) 149(1):123–127.
   PubMed Web of Science ®Google Scholar
• HULSMANN AR, RAATGEEP HR, SAXENA PR, KERREBIJNKF, DEJONGSTE JC: Bradykinin-induced contraction of human peripheral airways mediated by both bradykinin beta(2) and thromboxane prostartoid re-ceptors. Amer.J.Respir. Crit. Care Med. (1994) 150(4):1012–1018.
   PubMed Web of Science ®Google Scholar
• RICCIARDOLO FLM, NADEL JA, GRAF PD, BERTRAND C,• YOSHIHARA S, GEPPEITI P: Role of kinins in anaphylac-tic-induced bronchoconstriction mediated by tachykin-ins in guinea-pigs. Br.J. Pharmacol. (1994) 113(2):508–512. Demonstration of the implication of kinins and tachykinins in antigen-induced bronchoconstriction.
   Google Scholar
• MORI K, ASAKURA S, MORIKAWA N, CHAEN T, WATANABE N, MOGI G, TAKEYAMA M: Effect of terfenadine on substance P and VIP concentrations in nasal secretions from nasal allergy patients. Can. J Physiol. Pharmacol. (1994) 72\(Suppl. 1):266.
   Google Scholar
• JOOS GF, GERMONPRE PR, KIPS JC, PELEMAN RA, PAU-
   Google Scholar
• WELS RA: Sensory neuropeptides and the human lowerairways. Present state and future directions. Eur. Respir. J. (1994) 7(6):1161–1171. Excellent review presenting the implication of tachykinins in the airways and the potential interest of neurokinin antagonists in the treatment of asthma.
   Google Scholar
• WALSH DA, SALMON M, FEATHERSTONE R, WHARTON J,CHURCH MK, POLAK JM: Differences in the distribution and characteristics of tachykinin NKi binding sites between human and guinea pig lung. Br. J. Pharmacol. (1994) 113(4):1407–1415.
   PubMed Web of Science ®Google Scholar
• ICHINOSE M, NAKAJIMA N, TAKAHASHI T, YAMAUCHI H,• INOUE H, TAKISHIMA T: Protection against bradykinin-induced bronchoconstriction in asthmatic patients by neurokinin receptor antagonists. Lancet (1992) 340(21):1248–1251. First report of the clinical efficacy of a neurokinin antagonist.
   Google Scholar
• ARAMORI I, MORIKAWA N, ZENKOH J, ODONNELL N,IWAMI M, KOJO H, NOTSU Y, OKUHARA M, ONO S, NAKANISHI S: Subtype- and specles-selectivity of a tachykinin receptor antagonist, FK888, for cloned rat and human tachykinin receptors. Eur.J. Pharmacol. MoL Pharmacol. (1994) 269(2):277–281.
   PubMed Web of Science ®Google Scholar
• HAGIWARA D: Discovery of low molecular weight an-tagonists of substance-P. Recent developments and prospects as a therapeutic agent.J, Synth. Org. Chem.Jpn. (1994) 52(5)445–452.
   Google Scholar
• HAGIWARA D, MIYAKE H, IGARI N, KARINO M, MAEDA Y,
   Google Scholar
• FUJII T, MATSU° M: Studies on neurokinin antagonists.4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists. N-244R)-4-hy-droxy-1-1(1-methyl-1H-indo1-3-y1) carbony1R-proly1]-N-methyl-N-(phenylmethyl)-3-(2-naphthyl)-1-alanin amide and its related compounds. J. Med. Chem. (1994) 37(13):2090–2099. Discovery of an orally active pseudopeptide NKi antagonist by rational peptide drug design.
   Google Scholar
• KARLSSON U, NASSTROM J, BERGE OG: (+/-)-CP-96,345, an NKi receptor antagonist, has local anaesthetic-like effects in a mammalian sciatic nerve preparation. Regul. Peptide (1994) 52(1):39–46.
   PubMed Web of Science ®Google Scholar
• MACLEAN DB: Non-peptide NKi antagonists: a therapeu-tic role in inflammation? Can. J. Physiol. Pharmacol. (1994) 72\(Suppl. 2):24.
   Google Scholar
• ADVENIER C, GIRARD V, NALINE E, VILAIN P, EMONDS-ALT X: Antitussive effect of SR 48968, a non-peptide tachykinin NK2 receptor antagonist. Eur. J. Pharmacol. 250: 169–171.
   Google Scholar
• GIOLITH A, MAGGI CA: Structural comparison of NK2receptor agonists and antagonists. J. Comput. Aided Mol. Des. (1994) 8(3):341–344.
   PubMed Web of Science ®Google Scholar
• PATACCHINI R., DE GIORGIO R, GIACHETTI A, MAGGI CA:Different mechanism of tachykinin NK2 receptor block-ade by SR 48968 and MEN 10,627 in the guinea-pig Isolated gallbladder and colon. Eur. J. Pharmacol. (1994) 271:111–119.
   PubMed Web of Science ®Google Scholar
• BIRCH PJ, BEREFORD JM, BOWERS JS, HAGAN RM, HARRI-SON SM, ROGERS H: Lack of effect of a selective NK2 receptor antagonist in acute noceptive tests. Neuropep-tides (1993) 24(4):219.
   Google Scholar
• SMITH PW, MCELROY AB, PRITCHARD JM, DEAL MJ, EWANGB, HAGAN RM, IRELAND SJ, BALL D, BERESFORD I, SHELDRICK R, JORDAN CC, WARD P: Low molecular weight neurokinin NK2 antagonists. Bioorg. Med. Chem. Lett. (1993) 3(3):931–936.
   Google Scholar
• COOPER AWJ, ADAMS HS, BELL R, GORE PM, MCELROYAB, PRITCHARD JM, SMITH PW, WARD P: GR159897 and • related analogues as highly potent, orally active non- peptide neurokinin NK2 receptor antagonists. Bioorg. Med. Chem. Lett. (1994) 4(16):1951–1956. Discovery of a new, low-molecular weight non-peptide NK2 antago-nist with improved oral bioavailability.
   Google Scholar
• REGOLI D, GOBEIL F, NGUYEN QT, SEOANE PR, SALVINOJM, SAWUTZ DG: Bradykinin receptor types and B2 subtypes. Life Sci. (1994) 55(10):735–749.
   PubMed Web of Science ®Google Scholar
• RICCIARDOLO FLM, NADEL JA, BERTRAND C, YAMAWAKI I, CHAN B, GEPPETI P: Tackykinins and Mains in anti- gen-evoked plasma extravasation in guinea-pig nasal mucosa. Eur. J. Pharmacol. (1994) 261(1–2):127-132. Demonstration of the involvement of kinins and tachykinins in the nasal plasma extravasation observed in allergic guinea-pigs.
   Google Scholar
• BARNES PJ: Neuropeptides and airway pathophysiol-ogy. NeuroPeptides (1992) 22:7.
   Google Scholar
• RAHMAN M, LORDAL M, ALSAFFAR A, HELLSTROM PM:Intestinal motility responses to neuropeptkie gamma in vitro and in vivo in the rat comparison with neurok-inin-1 and neurokinin-2 receptor agonists. Acta Physiol. Scand. (1994) 151(4):497–505.
   PubMedGoogle Scholar
• SUZUKI N, MIZUNO K, GOMI Y: Tachykinin-induced contractions in the circular muscle of guinea pig ileum. ./Pn • J Pharmacol. (1994) 65(3)233–240.
   Google Scholar
• BARTHO L, MAGGI CA, WILHELM M, PATACCHINI R: Tachykinin NKi and NK2 receptors mediate atropine-resistant Heal circular muscle contractions evoked by capsaicin. Eur. J, Pharmacol. (1994) 259(2):187–193.
   PubMed Web of Science ®Google Scholar
• HELLSTROM PM, MURTHY KS, GRIDER JR, MAKHLOUF GM:Coexistence of three tachykinin receptors coupled to Ca++ signaling pathways in intestinal muscle cells. J. Pharinacol. Exp. Ther. (1994) 270(1):236–243.
   PubMed Web of Science ®Google Scholar
• PARRISH MB, RAINSFORD KD, JOHNSON DM, DANIEL EE:NK1 receptors mediated release of 6-keto-PGF(1-alpha) from the ex vivo perfused canine ileum. J. Pharmacol. Exp. Ther. (1994) 271(1):39–47.
   PubMed Web of Science ®Google Scholar
• TRAMONTANA M, MAGGI CA, EVANGELISTA S: Spas-molytic effect of the NK2-receptor-selective antagonist MEN 10,627 in rat small intestine. Jpn. J. Pharmacol. (1994) 65(3)281–283.
   Google Scholar
• BASILISCO G, PHILLIPS SF: A selective NK2 antagonistblocks the increase of canine colonic tone and heal contractions induced by the NK2 selective receptor agonist, ibeta-Ala(8)1 neurokinin A-(4-10). Alim. Phar-macol. Ther. (1994) 8(5):527–533.
   PubMed Web of Science ®Google Scholar
• MANTYH CR, VIGNA SR, MAGGIO JE, MANTYII PW, BOLLINGER RR, PAPPAS TN: Substance P binding sites on Intestinal lymphoid aggregates and blood vessels in Inflammatory bowel disease correspond to authentic NKi receptors. Neurosci. Lett. (1994) 178(2):255–259. Potential interest of neurokinin antagonists in the treatment of inflammatory bowel syndrome.
   Google Scholar
• POTHOULAIUS C, CASTAGLIUOLO I, LAMONT JT, JAFFERA, OKEANE JC, SNIDER RM, LEEMAN SE: CP 96345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc. Natl. Acad. Sci. USA (1994) 91:947–951.
   PubMed Web of Science ®Google Scholar
• VILLABLANCA AC, MURPHY CJ, REID 1W: Growth-pro-moting effects of substance P on endothelial cells in vitro. Synergism with calcitonin gene-related peptide, insulin, and plasma factors. Circ. Res. (1994) 75(6):1113–1120.
   Google Scholar
• ••
   Google Scholar
• CUMMINGS J, MACLELLAN A, LANGDON SP, SMYTH JF: Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg(1),D-Phe(5),D-Trp(7,9),Leu(11)1-substance P and EArg(6),D-Trp(7,9),Mephe(8)1-substance P (6-11) characterized by high-performance liquid chromatography. J. Pbarm. Biomed. Anal. (1994) 12(6):811–819.
   PubMed Web of Science ®Google Scholar
• WANG ZY, FENG DM, WANG YL, TUNG SR, WONG K, STRITCHARTZ GR, FOLKERS K, HAKANSON R: Pharma-cological assessment of spantide 11 analogues. Eur. J. Pharmacol. (1994) 260(2-3):121–128.
   PubMedGoogle Scholar
• THOMPSON SWN, DRAY A, URBAN L: Injury-induced plasticity of spinal reflex activity. NIQ neurokinin re-ceptor activation and enhanced A- and C-fiber mediated responses in the rat spinal cord in vitro. J. Neurosci. (1994) 14(6):3672–3687.
   Google Scholar
• URBAN L, THOMPSON SWN, DRAY A: Modulation of spinal excitability - co-operation between neurokininand excitatory amino acid neurotransmitters. Trends Neurosci. (1994) 17(10):432–438. Interesting review on the possible mechanisms of hyperalgesia.
   Google Scholar
• LEE HR, HO WZ, DOUGLAS SD: Substance P augments tumor necrosis factor release in human monocyte-de-rived macrophages. Clin. Diag. Lab. Immunol. (1994) 1(4):419–423.
   PubMedGoogle Scholar
• KALRA PS, DUBE MG, KALRA SP: The effects of inter-leukin ip on the hypothalamic tachykinin, neurokinin A. Brain Res. (1994) 662:178–184.
   PubMed Web of Science ®Google Scholar
• BRETDIBAT JL, KENT S, COURAUD JY, CREMINON C, DAN'TZER R: A behaviorally active dose of lipopolysac-charide increases sensory neuropeptides levels in mouse spinal cord. Neurosci. Lett. (1994) 173(1-2):205–209.
   PubMed Web of Science ®Google Scholar
• MALCANGIO M, BOWERY NG: Effect of the tachykinin NICi receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord. Br. J. Pharmacol. (1994) 113(2):635–641.
   PubMed Web of Science ®Google Scholar
• MANTYH PW, CATTON MD, BOEHMER CG, WELTON ML, PASSARO EP, MAGGIO JE, 'VIGNA SR: Receptors for sen-sory neuropeptides in human inflammatory diseases: Implication for the effector role of sensory neurons. Peptides (1989) 10:627–645.
   PubMed Web of Science ®Google Scholar
• DEKONINCK Y, SALTER MW, HENRY JL: Substance P released endogenously by high-intensity sensory stimulation potentiates purinergic inhibition of no-ciceptive dorsal horn neurons induced by peripheral vibration. Neurosci. Lett. (1994) 176(1):128–132.
   PubMed Web of Science ®Google Scholar
• RAVARD S, BETSCHART J, FARDIN V, FLAMAND 0, BLANCHARD JC: Differential ability of tachykinin NKI and NK2 agonists to produce scratching and grooming behaviours in mice. Brain Res. (1994) 651(1–2):199-208. Demonstration of atypical NK1 receptors in mice involved in the scratching and grooming behaviours induced by icy agonists.
   Google Scholar
• LEPRE M, OLPE HR, EVANS RH, BRUGGER F: Physiological and pharmacological characterization of the spinal tachykinin NK2 receptor. Eur.J. Pharmacol. (1994) 258(1-2):23–31.
   PubMed Web of Science ®Google Scholar
• HOSOKI R, YANAGISAWA M, GUO JZ, YOSHIOKA K, MAEHARA T, OTSUKA M: Effects of RP 67580, a tachykinin NKI receptor antagonist, on a primary af-ferent-evoked response of ventral roots in the neonatal rat spinal cord. Br. J. Pharmacol. (1994) 113(4):1141–1146.
   PubMed Web of Science ®Google Scholar
• SAKURADA T, YOGO H, MANOME Y, TANNO K, SAKURADA S, YAMADA A, KISARA K, OHBA M: Pharma- cological characterisation of NKI receptor antagonist, [D-Trp(7)]sendide, on behaviour elicited by substance Pin the mouse. Naunyn Schmiedeberg. Arch. Pharmacol. (1994) 350(4):387–392.
   PubMedGoogle Scholar
• ONOGI T, KAGAWA M, MINAMI M, KURAISHI Y, SATOHM: Intrathecal neuromedin C enhances mechanical nociception. Possible involvement of NMDA receptors. Eur. J. Pharmacol. (1994) 262(1-2):163–166.
   PubMed Web of Science ®Google Scholar
• SAKURADA T, MANOME Y, KATSUMATA K, TANNO K, SAKURADA S, OHBA M, KISARA K: Comparison of antago-nistic effects of sendide and CP-96,345 on a spinally mediated behavioural response in mice. Eur. J. Pharma-col. (1994) 261(1-2).85–90.
   PubMed Web of Science ®Google Scholar
• LEGAT FJ, GRIESBACHER T, LEMBECK F: Mediation bybradykinin of rat paw oedema induced by collagenase from Clostridium bistobnicum. Br. J. Pharmacol. (1994) 112(2): 453–460.
   PubMed Web of Science ®Google Scholar
• WILSONCROFT P, EUZGER H, BRAIN SD: Effect of a neurokinin-1 (N1(1) receptor antagonist on oedema formation induced by tachykinins, carrageenin and an allergic response in guinea-pig skin. Neuropeptides (1994) 26(6):405–411.
   PubMed Web of Science ®Google Scholar
• NAGAHISA A, ASAI R, KANAI Y, MURASE A, TSUCHIYA-NAKAGAKI M, NAKAGAKI T, SHIEH TC, TANIGUCHI K: Non-specific activity of (+/-)-CP-96345 in models of pain and inflammation. Br. J. Pharmacol. (1992) 107:273–275.
   PubMedGoogle Scholar
• RUPN1AK NMJ, JACKSON A: Non-specific inhibition ofdopamine receptor agonist-induced behaviour by the tachykinin NICi receptor antagonist CP-99,994 in guinea-pigs. Eur.]. Pharmacol. (1994) 262(1-2):171–175.
   PubMed Web of Science ®Google Scholar
• BOUNTRA C, BUNCE K, DALE T, GARDNER C, JORDAN C,TWISSELL D, WARD P: Anti-emetic profile of anon-pep-tide neurokinin NKi receptor antagonist, CP-99994, in ferrets. Eur. J. Pharmacol. (1993) 249:R3–R4.
   PubMedGoogle Scholar
• HARGREAVES RJ, TATTERSALL FD, RYCROFT W, WOOD-FORD K, LADDUWAHETTY T, KEOWN L, MERCHANT K, SWAIN C, MACLEOD A, BAKER R, FRANCIS B, BURNS D, BER E, CASCIERI P, METZGER J, MACINTYRE DE, WILLIAM-SON AR, IVERSEN LL, HILL RG: Evidence that the anti-emetic effects of NKi receptor antagonists are centrally mediated. Can. J. Physiol. Pharmacol. (1994) 72\(Suppl. 2):45.
   Google Scholar
• O'SHAUGHNESSY CT, CONNER HE: Investigation of therole of tachykinin NK1, NK2 receptors and CGRP recep-tors In neurogenic plasma protein extravasation in dura mater. Eur. J. Pharmacol. (1994) 263(1–2)193–198.
   Google Scholar
• O'SHAUGHNESSY CT, CONNOR HE: Activation of sensorynerves in guinea-pig isolated basiLar artery by nicotine. Evidence for inhibition of trigeminal sensory neuro-transmission by sumatriptan. Eur. j Pharmacol. (1994) 259(1):37–42.
   Google Scholar
• KAUMANN AJ, FRENKEN M, POSIVAL H, BROWN AM: Variable participation of 5-HTi-like receptors and 5-HT2 receptors in serotonin-induced contractions of human Isolated coronary arteries. 5-HTi-like receptors resem-ble cloned 5-HT wp receptors. Circulation (1994) 90(3):1141–1153.
   Google Scholar
• MACINTYRE PD, BHARGAVA B, HOGG KJ, GEMMILL JD,HILLIS WS: Effect of subcutaneous sumatriptan, a selec-tive 5-HT1 agonist, on the systemic, pulmonary and coronary circulations. Circulation (1993) 87(2):401–405.
   PubMed Web of Science ®Google Scholar
• LEE WS, MOUSSAOUI SM, MOSKOWITZ MA oral or parenteral RPR 100893 (a non-peptide NICi receptor antagonist) of neurogenic plasma protein ex-travasation within guinea-pig dura mater and conjunc-tiva. Br. J. Pharmacol. (1994) 112(3):920–924. Potential interest of NKi antagonists in the treatment of migraine headache.
   Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, HILL RG, HARGREAVES RJ: The non-peptide netwolcinin-1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br.J. Pharmacol. (1993) 108:11–12.
   PubMed Web of Science ®Google Scholar
• PEYRONEL JF: Synthesis and structure-activity relation-ships in perhydroisoindole substance P antagonists. XIIth International Symposium on Medicinal Chemisay. Part's, France September 19–23 (1994):ML33.
   Google Scholar
• JOSIEN H, LAVIELLE S, BRUNISSEN A, SAFFROY M, TOR-RENS Y,BEAUJOUAN JC, GLO'WINSKI J, CHASSAING G: Design and synthesis of side-chain confortnationally restricted phenylalanines and their use for structure-activity studies on tachykinin NICi receptor. J. Med. Chem. (1994) 37(11):1586–1601.
   PubMed Web of Science ®Google Scholar
• FONG TM, YU H, CASCIERI MA, UNDERWOOD D, SWAINCJ, STRADER CD: Interaction of glutamine 165 in the fourth transmembrane segment of the human neurok-inin-1 receptor with quinuclidine antagonists. J. Biol. Chem. (1994) 269(21):14957–14961.
   PubMed Web of Science ®Google Scholar
• LADDUWAHETTY T, KEOWN L, CASCIERI MA, SADOWSKIS: Morpholine-based substance P antagonists. Assess-ment of the 3-point binding model. Bioorg. Med. Chem. Lett. (1994) 4(16):1917–1920.
   Google Scholar
• GETHER U, NILSSON L, LOWE JA, SCHWARTZ TW: Specificresidues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP 96,345. J. Biol. Chem. (1994) 269(39):23959–23964.
   PubMed Web of Science ®Google Scholar
• PALADIN° J, KUCHARCZYK N, MORRIS AD, THIBAULT-NAZE M, MAHIEU JP, SERKIZ B, VOLLAND JP, AUTISSIER C, FAUCHERE JL: Estimation of blood levels of en-dothelin and neurokinin receptor antagonists at the rat portal and jugular veins after oral administration as a tool in peptide drug design. Drug Des. Discov. (1994) 12:121–128.
   PubMedGoogle Scholar
• HARRISON T, WILLIAMS BJ, SWAIN CJ, BALL RG: Piperid-ine-ether based liNKi antagonists. 1. Determination of the relative and absolute stereochemical requirements. Thom. Med. Chem. Lett. (1994) 4(21):2545–2550.
   Google Scholar
• SWAIN CJ, CASCIERI MA, OWENS A, SAARI W, SADOWSKI S, STRADER C, TEALL M, VANNIEL MB, WILLIAMS BJ: Acyclic NICi antagonists. Replacements for the benzhy-dryl group. Bloorg. Med. Chem. Lett. (1994) 4(18):2161–2164.
   Web of Science ®Google Scholar
• WILLIAMS BJ, TEALL M, MCKENNA J, HARRISON T, SWAIN CJ, CASCIERI MA, SADOWSKI S, STRADER C, BAKER R: Acyclic NICi antagonists. 2-benzhydry1-2-aminoethyl ethers. Bioorg. Med. Chem. Lett. (1994) 4(101903–1908. Design of new NK1 antagonists derived from aminoacids.
   Google Scholar
• MACLEOD AM, MERCHANT KJ, LEWIS RT, SADOWSKI S, CASCIERI MA: Orally active non-peptide substance P receptor antagonists derived from L-tryptophan. Xlith International Symposium on Medicinal Chemisay Paris, France, September 19-23 (1994):P273.
   Google Scholar
• STABLES JM, BERESFORD UM, ARKINSTALL S, IRELAND SJ, WALSH DM, SEALE PW, WARD P, HAGAN RM: GR 138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors. Neuropeptides (1994) 27:333–341.
   PubMed Web of Science ®Google Scholar
• MUSSAP CJ, BURGHER E: Binding sites for [1251]-Bolton-Hunter scyliorhinin II in guinea-pig ileum. Radioligand binding, functional and autoradiographic. Naunyn Schmiedebog. Arch. Pharmacol. (1994) 350(3):301–309.
   Google Scholar
• BODEN P, EDEN JM, HODGSON J, HORWELL DC, HOWSON W, HUGHES J, MCKNIGHT AT, MEECHAM K, PRITCHARD MC: The rational development of small molecule tachykinin NK3 receptor selective antago-nists. The utilisation of a dipeptide chemical library in drug design. Bioorg. Med. Chem. Lea. (1994) 4(14):1679–1684. First potent pseudopeptide NK3 antagonist.
   Google Scholar
• EMONDS-ALT X, BICHON D, DUCOUX JP, HEAULME M, MILOUX B, PONCELET M, PROIETTO V, VANBROECK D, VLLAIN P, NELIAT G, SOUBRIE P, LE FUR G, BRELIERE JC: SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. (1994) 56(1):27–32. First potent non-peptide NK3 antagonist.
   Google Scholar
• PINNOCK RD, SUMANCHAUHAN N, CHUNG FZ, WEBDALE L, MADDEN Z, HILL DR, WOODRUFF GN: Charac-terization of tachykinin mediated increases in [Ca2+](0 In chinese hamster ovary cells expressing human tachykinin NK3 receptors. Eurj. Pharmacol. Mol. Phar-macol. (1994) 269(1):73–78.
   PubMed Web of Science ®Google Scholar
• SUMANCHAUHAN N, GRIMSON P, GUARD S, MADDEN Z, CHUNG FZ, WATLING K, PINNOCK R, WOODRUF G: Characterisation of [I-1251[MePhe(7)]neurokinin B binding to tachykinin NIC3 receptors. Evidence for interspecies variance. Eur. J. Pharrnacol, Mol. Pharmacol. (1994) 269(1):65–72.
   PubMed Web of Science ®Google Scholar